Physician profile
Sara Rippel
NPI 1346403466
$33,384.32
in general payments reported to CMS, 2019-2025
31 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $196 · 2021: $1,520 · 2022: $2,713 · 2023: $1,001 · 2024: $8,563 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $1,973 · Food and Beverage: $1,771 · Consulting Fee: $804 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,964.66 |
| Travel and Lodging | $1,972.68 |
| Food and Beverage | $1,771.12 |
| Consulting Fee | $804.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18,572.39 | 2022-2025 | Dupixent |
| Genzyme Corporation | $12,209.99 | 2021-2024 | |
| Abbvie INC. | $550.56 | 2019-2025 | Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.31 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $330.15 | 2023-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $243.89 | 2022-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $130.96 | 2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $126.05 | 2020-2024 | Entyvio |
| Pfizer INC. | $123.94 | 2019 | |
| Janssen Scientific Affairs, LLC | $105.84 | 2022-2025 | |
| Novo Nordisk INC | $92.57 | 2025 | Wegovy, Saxenda |
| Celgene Corporation | $89.82 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $46.68 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $42.05 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $35.46 | 2022-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $33.49 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $31.34 | 2023 | Sutab, Suflave |
| Daiichi Sankyo INC. | $21.48 | 2024 | Injectafer |
| Evoke Pharma, INC. | $20.46 | 2023 | Gimoti |
| Albireo Pharma, INC. | $18.26 | 2022 | |
| Madrigal Pharmaceuticals | $17.35 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $17.06 | 2023 | Rebyota |
| Pharmacosmos Therapeutics INC. | $15.71 | 2021 | |
| Travere Therapeutics, INC. | $14.80 | 2019 | |
| Neuraxis, INC. | $13.86 | 2020 | |
| Aimmune Therapeutics, INC. | $13.19 | 2024 | |
| Shire North American Group INC | $11.85 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.81 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$39,706.98 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Rippel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.